NO20065191L - Fremgangsmate for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav - Google Patents

Fremgangsmate for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav

Info

Publication number
NO20065191L
NO20065191L NO20065191A NO20065191A NO20065191L NO 20065191 L NO20065191 L NO 20065191L NO 20065191 A NO20065191 A NO 20065191A NO 20065191 A NO20065191 A NO 20065191A NO 20065191 L NO20065191 L NO 20065191L
Authority
NO
Norway
Prior art keywords
acid
inhibitors
dipeptidyl
boc protected
intermediates
Prior art date
Application number
NO20065191A
Other languages
English (en)
Inventor
Michael Politino
Matthew M Cadin
Paul M Skonezny
Jason G Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20065191L publication Critical patent/NO20065191L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C12N1/066—Lysis of microorganisms by physical methods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0016—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1)
    • C12N9/0018—Phenylalanine dehydrogenase (1.4.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • C12P13/222—Phenylalanine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P15/00—Preparation of compounds containing at least three condensed carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/02—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a cytochrome as acceptor (1.2.2)
    • C12Y102/02001—Formate dehydrogenase (cytochrome) (1.2.2.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En fremgangsmåte for produksjon av cyklopropyl-kondenserte pyrrolidin-baserte inhibitorer av dipeptidyl-peptidase IV er gitt som anvender et BOC-beskyttet amin med struktur 3, fremstilt ved å underkaste en syre med struktur 1 for reduktiv aminering ved behandling av syren med ammoniumformiat, nikotinamid-adenin-dinukleotid, ditiotreitol og delvis renset fenylalanin-dehydrogenase/formiat-dehydrogenase enzymkonsentrat (PDH/FDH) og uten isolering, behandle det resulterende amin med struktur 2 med di-tert-butyl-dikarbonat for å danne det BOC-beskyttede amin.
NO20065191A 2004-04-14 2006-11-13 Fremgangsmate for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav NO20065191L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56198604P 2004-04-14 2004-04-14
PCT/US2005/012615 WO2005106011A2 (en) 2004-04-14 2005-04-13 Process for preparing dipeptidyl iv inhibitors and intermediates therefor

Publications (1)

Publication Number Publication Date
NO20065191L true NO20065191L (no) 2006-11-13

Family

ID=35242266

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20065191A NO20065191L (no) 2004-04-14 2006-11-13 Fremgangsmate for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav
NO20151145A NO20151145L (no) 2004-04-14 2015-09-07 Fremgangsmåte for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav
NO20151146A NO20151146L (no) 2004-04-14 2015-09-07 Fremgangsmåte for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20151145A NO20151145L (no) 2004-04-14 2015-09-07 Fremgangsmåte for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav
NO20151146A NO20151146L (no) 2004-04-14 2015-09-07 Fremgangsmåte for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav

Country Status (16)

Country Link
US (4) US7741082B2 (no)
EP (3) EP2894227A3 (no)
JP (3) JP4896872B2 (no)
KR (1) KR101269813B1 (no)
CN (3) CN1968925B (no)
AR (1) AR048695A1 (no)
AU (1) AU2005238442A1 (no)
BR (1) BRPI0509890A (no)
CA (1) CA2563903A1 (no)
IL (1) IL178520A0 (no)
NO (3) NO20065191L (no)
PE (1) PE20060255A1 (no)
RU (1) RU2373194C2 (no)
TW (1) TW200540274A (no)
WO (1) WO2005106011A2 (no)
ZA (1) ZA200608304B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7420079B2 (en) * 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US7741082B2 (en) 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
WO2007085933A2 (en) * 2006-01-25 2007-08-02 Glenmark Pharmaceuticals Limited Process for the preparation of n-[1-(s)-ethoxycarbonyl-1-butyl]-(s)-alanine-dmt complex and its use in the preparation of perindopril
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0917675A2 (pt) 2008-08-15 2015-12-01 Boehringer Ingelheim Int compostos orgânicos para cura de ferida
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
CN104906582A (zh) 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
CN106177958A (zh) 2009-02-13 2016-12-07 勃林格殷格翰国际有限公司 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
CN102459610B (zh) * 2009-04-08 2014-12-17 阿斯利康(瑞典)有限公司 表达pdh和fdh酶的遗传稳定性质粒
MY145258A (en) * 2009-07-06 2012-01-11 Univ Sains Malaysia A system for producing l-homophenylalanine and a process for producing l-homophenylalanine
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
FR2956400A1 (fr) * 2010-02-15 2011-08-19 Finorga Procede de preparation de composes adamantyles
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP2539321A1 (en) 2010-05-05 2013-01-02 Assia Chemical Industries Ltd. Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
WO2012028721A1 (en) 2010-09-03 2012-03-08 Sandoz Ag PROCESS FOR THE REDUCTIVE AMINATION OF α-KETO CARBOXYLIC ACIDS
EP2608788A1 (en) 2010-10-04 2013-07-03 Assia Chemical Industries Ltd. Polymorphs of saxagliptin hydrochloride and processes for preparing them
US9125729B2 (en) * 2011-10-21 2015-09-08 Aquatic Therapy Innovations, Llc Buoyancy-based cervical traction system
WO2013081100A1 (ja) * 2011-11-30 2013-06-06 積水メディカル株式会社 アダマンチルヒダントイン化合物
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2867206A2 (en) 2012-07-02 2015-05-06 Ranbaxy Laboratories Limited Saxagliptin salts
CN103539724B (zh) * 2012-07-12 2017-09-26 博瑞生物医药（苏州）股份有限公司 沙格列汀单一立体异构体的新晶型和纯化方法
WO2014108830A1 (en) 2013-01-10 2014-07-17 Wockhardt Limited A process for preparing pharmaceutically acceptable salt of saxagliptin
CN103265473A (zh) * 2013-06-04 2013-08-28 上海同昌生物医药科技有限公司 一种生产沙格列汀的方法
ITMI20131029A1 (it) * 2013-06-20 2014-12-21 Chemelectiva S R L Intermedi utili per la preparazione di saxagliptina
CN103555683B (zh) * 2013-11-19 2015-11-18 南京博优康远生物医药科技有限公司 一种沙格列汀手性中间体的合成方法
WO2015087262A1 (en) 2013-12-11 2015-06-18 Ranbaxy Laboratories Limited Process for the preparation of saxagliptin and its intermediates
CN103724254A (zh) * 2013-12-23 2014-04-16 上海应用技术学院 一种沙克列汀中间体的制备方法
CN105315189A (zh) * 2014-05-29 2016-02-10 上海医药工业研究院 一种制备（5s）-5-氨基羰基-4,5-二氢-1h-吡咯-1-羧酸-1（1,1-二甲基乙基）酯的方法
CN104098505A (zh) * 2014-07-31 2014-10-15 天津民祥生物医药科技有限公司 一种沙格列汀的制备方法
CN104177284B (zh) * 2014-08-01 2016-08-24 常州大学 合成3-氮杂二环[3,1,0]己基-1-甲醛的方法
CN104293844B (zh) * 2014-08-26 2017-10-10 苏州永健生物医药有限公司 一种特拉匹韦中间体的合成方法
CN104356046B (zh) * 2014-11-02 2017-04-05 浙江医药高等专科学校 环烷基取代的环己烷羧酸酰胺类衍生物及其用途
CN104356048B (zh) * 2014-11-02 2016-08-24 浙江医药高等专科学校 环己烷羧酸酰胺类衍生物、其制备方法和用途
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN105130879B (zh) * 2015-07-24 2018-03-02 沧州那瑞化学科技有限公司 （R）‑3‑Boc‑氨基哌啶的制备方法
CN106554301B (zh) * 2015-09-30 2018-09-21 深圳翰宇药业股份有限公司 一种沙格列汀关键中间体的制备方法
CN106755152B (zh) * 2017-01-23 2020-06-16 苏州引航生物科技有限公司 一种制备奥格列汀中间体的方法
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy
CN109970620B (zh) * 2017-12-27 2022-07-12 江苏威凯尔医药科技有限公司 一种制备沙格列汀中间体的方法
RU2712097C1 (ru) * 2018-09-28 2020-01-24 Общество с ограниченной ответственностью "Необиотек" Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа, соединения (варианты)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1023896A (ja) * 1996-05-07 1998-01-27 Unitika Ltd 組換えプラスミド、それにより形質転換された大腸菌、その培養物及びそれを用いたアミノ酸又はその誘導体の製造方法
IL120873A0 (en) 1996-05-24 1997-09-30 Tanabe Seiyaku Co Process for preparing optically active 2-halogen-3-hydroxypropionic acid ester
US6068991A (en) 1997-12-16 2000-05-30 Bristol-Myers Squibb Company High expression Escherichia coli expression vector
WO2000004179A1 (en) 1998-07-15 2000-01-27 Bristol-Myers Squibb Company Stereoselective reductive amination of ketones
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US20020042124A1 (en) 2000-08-16 2002-04-11 Patel Ramesh N. Stereoselective reduction of substituted oxo-butanes
US6828119B2 (en) * 2001-01-04 2004-12-07 Bristol Myers Squibb Company Enzymatic deprotection of amines and hydroxides
US6800465B2 (en) 2001-04-03 2004-10-05 Bristol-Myers Squibb Company D-hydantoinase from Ochrobactrum anthropi
US7087418B2 (en) * 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
TW200538122A (en) 2004-03-31 2005-12-01 Bristol Myers Squibb Co Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7741082B2 (en) 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
TW200536827A (en) 2004-05-04 2005-11-16 Bristol Myers Squibb Co Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
US7214702B2 (en) 2004-05-25 2007-05-08 Bristol-Myers Squibb Company Process for producing a dipeptidyl peptidase IV inhibitor

Also Published As

Publication number Publication date
IL178520A0 (en) 2007-02-11
CN1968925A (zh) 2007-05-23
CA2563903A1 (en) 2005-11-10
CN103215320A (zh) 2013-07-24
US20130204012A1 (en) 2013-08-08
KR101269813B1 (ko) 2013-05-30
EP1737970A4 (en) 2011-08-24
WO2005106011A3 (en) 2006-10-26
BRPI0509890A (pt) 2007-10-30
JP2011177177A (ja) 2011-09-15
NO20151146L (no) 2006-11-13
US7741082B2 (en) 2010-06-22
EP2894227A2 (en) 2015-07-15
NO20151145L (no) 2006-11-13
WO2005106011A2 (en) 2005-11-10
EP2894227A3 (en) 2015-08-12
RU2373194C2 (ru) 2009-11-20
JP5715169B2 (ja) 2015-05-07
TW200540274A (en) 2005-12-16
AR048695A1 (es) 2006-05-17
US8222009B2 (en) 2012-07-17
US20050260712A1 (en) 2005-11-24
EP3000893A2 (en) 2016-03-30
JP2013121351A (ja) 2013-06-20
US20100291642A1 (en) 2010-11-18
ZA200608304B (en) 2008-07-30
EP1737970A2 (en) 2007-01-03
CN103215320B (zh) 2015-09-23
US20120276600A1 (en) 2012-11-01
CN1968925B (zh) 2013-04-17
CN103215321A (zh) 2013-07-24
EP3000893A3 (en) 2016-06-29
JP4896872B2 (ja) 2012-03-14
JP5210406B2 (ja) 2013-06-12
AU2005238442A1 (en) 2005-11-10
PE20060255A1 (es) 2006-03-31
RU2006140134A (ru) 2008-05-27
KR20070006903A (ko) 2007-01-11
CN103215321B (zh) 2015-09-09
JP2007532137A (ja) 2007-11-15
US8809024B2 (en) 2014-08-19
US8361761B2 (en) 2013-01-29

Similar Documents

Publication Publication Date Title
NO20065191L (no) Fremgangsmate for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav
WO2008013997A3 (en) Fluorescent substrates for monoamine transporters as optical false neurotransmitters
CA2405486A1 (fr) Procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
CR20110698A (es) Proceso para la producción de derivados de amina ópticamente activos (divisional exp. n° 8975)
NO20060703L (no) Fremgangsmate for fremstilling av cis-4-fluor-1-prolinderivater
MY141797A (en) Biochemical synthesis of 6-amino caproic acid
EP1406622A4 (en) DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES
EP1406872A4 (en) DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES
TW200531695A (en) Dipeptidyl peptidase inhibitors
WO2004085661A3 (en) Process to chiral beta-amino acid derivatives
IL180354A0 (en) Process for the preparation of atomoxetine hydrochloride
TW200618796A (en) Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
WO2009018065A3 (en) Novel glucokinase activators and methods of using same
ATE381559T1 (de) Adamantan- und azabicyclooctan- und - nonanderivate, verfahren zu deren herstellung und deren verwendung als dpp-iv-inhibitoren
PE20060307A1 (es) Proceso de amonolisis enzimatica para preparacion de compuestos intermediarios para inhibidores de dipeptidilo peptidasa iv
WO2003008379A1 (fr) Composes azasucre
TW200718688A (en) Fluorinated ryridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls
NO20076000L (no) Aminosyrederivater
IL187640A0 (en) Method for preparing clopidogrel and intermediates used therein
IL186014A (en) Process for the preparation of 2-azabicyclo[3.3.0] octane-3-carboxylic acid derivatives
DK0904348T3 (da) Fremgangsmåde til fremstilling af aminoalkoholer og derivater deraf
NO20050540L (no) Krystallinske former av kinoxalin-2-karboksylsyre [4-karbamT-1-(3-fluorbenzyl)-2,7-dihydroksy-7-metyloktyl]-ami
WO2003080855A3 (en) Deracemisation of amines
PL1667987T3 (pl) Sposób wytwarzania mykofenolanu mofetylu
DK1334176T3 (da) Mikroorganismer, der producerer L-glutamin, og fremgangsmåder til produktion af L-glutamin under anvendelse af samme

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTRAZENECA AB, SE

FC2A Withdrawal, rejection or dismissal of laid open patent application